SCHEMBL526369

SCHEMBL526369

Nc1cc(Br)ccc1OC(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.40
L3MBTL1 Q9Y468 3/20 0.39
ALDH1A1 P00352 2/20 0.39
MAPK1 P28482 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
MAOA P21397 1/20 0.37
MAOB P27338 1/20 0.37
ALPL P05186 4/20 0.36
KDR P35968 3/20 0.36
EPHB4 P54760 2/20 0.36
TEK Q02763 2/20 0.36
PDE2A O00408 1/20 0.35
KDM4E B2RXH2 1/20 0.34
MEN1 O00255 1/20 0.34
USP2 O75604 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
G6PD P11413 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30279579 0.85 L3MBTL1 (0.36) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL410815 0.84 HRH4 (0.46) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL29514602 0.84 HRH4 (0.46) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL30279586 0.83 TRPV1 (0.39) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL30279587 0.83 TRPV1 (0.39) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL25875505 0.82 L3MBTL1 (0.34) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL4704298 0.81 MAPK1 (0.43) HRH4L3MBTL1ALDH1A1MAPK1TDP1
SCHEMBL398001 0.79 ALDH1A1 (0.44) L3MBTL1ALDH1A1MAPK1TDP1PDE2A
SCHEMBL30397188 0.79 ALDH1A1 (0.44) L3MBTL1ALDH1A1MAPK1TDP1PDE2A
SCHEMBL5502229 0.79 ALDH1A1 (0.44) L3MBTL1ALDH1A1MAPK1TDP1PDE2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104817489-B A kind of heterocycle biphenyl aryl urea compounds with antitumor activity and its preparation method and application 西安交通大学 2017-06-27 CN claimed
CN-104817489-A Heterocyclic biphenyl aryl urea compound with antitumor activity, preparation method and application thereof UNIV XI AN JIAOTONG 2015-08-05 CN claimed
EP-4747242-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE Horizon Therapeutics Ireland Dac (IE) 2026-05-27 EP disclosed
EP-4739306-A2 POLO-LIKE KINASE 1 INHIBITORS Cervero Therapeutics, LLC (US) 2026-05-13 EP disclosed
EP-4665339-A1 INHIBITING ALPHA V BETA 8 INTEGRIN Morphic Therapeutic, Inc. (US) 2025-12-24 EP disclosed
EP-4653443-A1 STEREOISOMER AND DEUTERATED DERIVATIVE OF PYRAZOLOQUINAZOLINE COMPOUND AND USE Phil Rivers Technology Co., Ltd (CN) 2025-11-26 EP disclosed
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS INTERLINE THERAPEUTICS INC (US) 2025-11-13 US disclosed
CN-115362147-B Herbicidal compounds 先正达农作物保护股份公司 2025-06-13 CN disclosed
US-20250145585-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE HORIZON THERAPEUTICS IRELAND DAC (IE) 2025-05-08 US disclosed
CN-119698416-A Imidazo (1, 2-A) pyridine derivatives as RIPK2 inhibitors 英特莱治疗公司 2025-03-25 CN disclosed
EP-4518974-A1 IMIDAZO(1,2-A)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS Interline Therapeutics, Inc. (US) 2025-03-12 EP disclosed
EP-1958666-A1 Heterocyclic-substituted alkanamides as therapeutic compounds Speedel Experimenta AG (CH) 2008-08-20 EP disclosed
US-20080176947-A1 Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors NOVARTIS AG (CH) 2008-07-24 US disclosed
WO-2008074788-A1 SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 WO disclosed
WO-2008074788-A1 SUBSTITUTED PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2008-06-26 WO disclosed
US-20080044355-A1 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease VERTEX PHARMACEUTICALS INCORPORATED 2008-02-21 US disclosed
US-20080009524-A1 Modulators of ATP-binding cassette transporters VERTEX PHARMACEUTICALS INCORPORATED 2008-01-10 US disclosed
EP-1856032-A1 HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS Speedel Experimenta AG (CH) 2007-11-21 EP disclosed
WO-2007087066-A2 1-(BENZO [D] [1,3] DI0X0L-5-YL) -N- (PHENYL) CYCLOPROPANE- CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS FOR THE TREATMENT OF CYSTIC FIBROSIS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-08-02 WO disclosed
WO-2006095020-A1 HETEROCYCLIC-SUBSTITUTED ALKANAMIDES USEFUL AS RENIN INHIBITORS SPEEDEL EXPERIMENTA AG (CH) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176947-A1 Heterocyclic-Substituted Alkanamides Useful as Renin Inhibitors REN, ACE, AGTR1 HRH4 147/4885L3MBTL1 4043/4885ALDH1A1 146/4885
US-20080009524-A1 Modulators of ATP-binding cassette transporters CFTR, ABCB1, ABCC2 HRH4 2082/4885L3MBTL1 3601/4885ALDH1A1 1961/4885
US-20250346593-A1 IMIDAZO(1,2-1)PYRIDINE DERIVATIVES AS RIPK2 INHIBITORS RIPK2, RIPK1, RIPK4 HRH4 3314/4885L3MBTL1 3544/4885ALDH1A1 3792/4885
US-20250145585-A1 HETEROCYCLIC INHIBITORS OF IGF-1R FOR TREATMENT OF DISEASE IGF1R, TSHR, TRHR HRH4 1593/4885L3MBTL1 3821/4885ALDH1A1 1332/4885
US-20080044355-A1 including cystic fibrosis transmembrane conductance regulator (\"CFTR\"); amido-phenyl derivatives; genetic disorders; respiratory system disorders, cystic fibrosis, hereditary emphysema, hereditary hemochromatosis, coagulation-fibrinolysis and lipid processing deficiencies, lysosomal storage disease CFTR, ABCB4, ABCF2 HRH4 673/4885L3MBTL1 1544/4885ALDH1A1 4147/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.